Group 1 - ENDRA Life Sciences Inc. announced an aggregate of $4.9 million in commitments for a private placement led by institutional and cryptocurrency investors [1] - The proceeds from the offering will be utilized to launch a diagnostic tool for monitoring metabolic dysfunction associated liver disease (MASLD) and metabolic dysfunction associated steatohepatitis (MASH) [1]